These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. In vivo assessment of thrombosis and fibrinolysis during acute myocardial infarction. Jaffe AS; Eisenberg PR; Wilner GD Prog Hematol; 1987; 15():71-89. PubMed ID: 3332392 [No Abstract] [Full Text] [Related]
16. Recombinant tissue plasminogen activator (rt-PA): is it the thrombolytic agent of choice for an evolving acute myocardial infarction? Sherry S Am J Cardiol; 1987 Apr; 59(9):984-9. PubMed ID: 3105303 [No Abstract] [Full Text] [Related]
17. [Antithrombosis therapy in ischemic heart disease]. Cerveró Martí A; Echánove Errazquin I; Noguera Sanchis R Med Clin (Barc); 1988 Apr; 90(16):670-4. PubMed ID: 3294537 [No Abstract] [Full Text] [Related]
18. Why targeting? Physiological, pharmacological, and economic aspects. Fears R Ann N Y Acad Sci; 1992 Dec; 667():343-56. PubMed ID: 1309055 [No Abstract] [Full Text] [Related]
19. New thrombin inhibiting strategies for coronary artery disease. Shah PK; Parikh A Indian Heart J; 1995; 47(4):381-6. PubMed ID: 8557285 [No Abstract] [Full Text] [Related]
20. Viewpoint: megatrials and the development of antithrombotics. Polak M Circulation; 2006 Jun; 113(25):f97. PubMed ID: 16801471 [No Abstract] [Full Text] [Related] [Next] [New Search]